EducationPhD University of Chicago, 2004 (Health Economics, Public Policy)
MS University of North Carolina (Chapel Hill), 1999 (Biostatistics)
MS University of Toledo, 1997 (Pharmaceutical Sciences)
BS Jadavpur University, 1995 (Pharmaceutical Sciences)
Contact Infoemail: firstname.lastname@example.org
web site: http://faculty.washington.edu/basua/
office: H-375Q, Health Sciences Building
Magnuson Health Sciences Center
1959 NE Pacific St.
Seattle, WA 98195-7630
campus box: 357630
Anirban Basu's work sits at the intersection of microeconomics, statistics, and health policy. His research focuses on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research.
Currently the Stergachis Family Endowed Professor and Director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington, Basu also serves as faculty member in the Department of Health Services and as an adjunct in the Department of Economics. Previously, Basu taught on the faculty of the University of Chicago Department of Medicine, where he remains an external affiliate of the Center for Health and the Social Sciences.
In addition to his position as a faculty research fellow at the National Bureau of Economic Research, Basu is as an associate editor for Health Economics, Journal of Health Economics, and Observational Studies, and has served as panelist or speaker at many economics and health studies conferences, nationally and abroad.
- HSERV 525
Advanced Health Services Research Methods III - Causal Inference Using Observational Data
Sanders GD, Maciejewski ML, Basu A. Overview of Cost-effectiveness Analysis. JAMA. 2019 Mar 11. doi: 10.1001/jama.2019.1265. [Epub ahead of print] PMID: 30855638
Basu A, Veenstra DL, Carlson JJ, Wang WJ, Branch K, Probstfield J. How can clinical researchers quantify the value of their proposed comparative research? Am Heart J. 2018 Dec 8. pii: S0002-8703(18)30337-5. doi: 10.1016/j.ahj.2018.12.003. [Epub ahead of print] PMID: 30638543
Basu A, Maciejewski ML. Choosing a Time Horizon in Cost and Cost-effectiveness Analyses. JAMA. 2019 Feb 21. doi: 10.1001/jama.2019.1153. [Epub ahead of print] PMID: 30789668
Basu A, Sohn MW, Bartle B, Chan KCG, Cooper JM, Huang E. Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model. Med Decis Making. 2019 Feb;39(2):137-151. doi: 10.1177/0272989X18817521. Epub 2019 Jan 17. PMID: 30654704
PI: Basu Dates: 6/1/2016 - 5/30/2017
PI: Basu Dates: 9/1/2015 - 8/31/2016
PI: Coe Dates: 7/1/2015 - 6/30/2019
PI: Veenstra Dates: 7/1/2015 - 6/30/2016
PI: Basu Dates: 6/1/2015 - 5/31/2016
PI: Flum Dates: 5/1/2015 - 4/30/2019
PI: Basu Dates: 2/1/2015 - 1/31/2017
PI: Zatzick Dates: 7/1/2014 - 6/30/2019
PI: Veenstra Dates: 10/1/2013 - 9/30/2018
PI: Basu Dates: 12/28/2011 - 8/31/2016
Comparative effectiveness research is a growing field that aims to generate evidence to improve health care decisions for patients and providers. It examines the benefits and risks of different medical or healthcare interventions, including drugs and medical technology. The results of these comparison studies are used by medical professionals to make better informed healthcare decisions and thereby improve patient care.
- Researchers partner with Penn to study costs of Alzheimer's and dementia care
- Anirban Basu on panel that updated guide to caregiversâ€™ decisions
- UW Professors Named American Statistical Association Fellows
- Study Examines Outcomes, Costs after Return Visits to ER
- Outcomes from patient hospitalization after return visits to ER
- Drug projected at $1 million has spark mulling installment plan
- 2014's Best & Worst States at Combating the High Cost of Lung Cancer
- Politics Gets in the Way of Signing up for Health Insurance
- Political Polarization and Health Insurance
- Where Are U.S. Healthcare Costs Going?
- Project to Gauge Effects of Affordable Care Act in Washington State